Skip to main navigation menu Skip to main content Skip to site footer

Detection of Legionella Pneumophila as an etiologic agent of community-acquired severe pneumonia

Detección de Legionella Pneumophila como agente etiológico de neumonía grave adquirida en la comunidad




Section
Original Articles

How to Cite
Hernández, J. I., Abello Polo, V., Medina Orjuela, A., Pacheco Gaona, J. O., & Ríos, D. I. (2002). Detection of Legionella Pneumophila as an etiologic agent of community-acquired severe pneumonia. Journal of Medicine and Surgery Repertoire, 11(3), 74-79. https://doi.org/10.31260/RepertMedCir.v11.n3.2002.288

Dimensions
PlumX
license

   

José Ignacio Hernández
    Virginia Abello Polo
      Adriana Medina Orjuela
        Javier Orlando Pacheco Gaona
          Dora Inés Ríos

            The microorganisms isolated most frequently in patients with severe community-acquired pneumonia (CAP) are: Streptococcus pneumoniae, Legionella pneumophila and Gram-negative organisms. In Colombia there have been no reports of Legionella pneumonia since a special culture medium is required for its isolation. In order to determine the role of this microorganism as an etiological agent of severe pneumonia acquired in the community, a descriptive study was conducted on a population of 187 patients, who constitute the totality of cases of CAP that entered the Hospital de San José, in the city of Bogotá, Colombia, between October 1999 and June 2001 and of which 20 represent cases of severe CAP. In this study, Legionella pneumophila was not isolated as an etiological agent of severe CAP, therefore the therapeutic indication of macrolides in our environment, suspecting this pathology, should be re-evaluated.


            Article visits 398 | PDF visits 681


            Downloads

            Download data is not yet available.

            1. American thoracic society board of directors: Guidelines for the Initial Management of Adults with Community Acquired Pneumonia: Diagnosis, Assessment of Severity and Initial Antimicrobial Therapy. Am Rev Resp Dis. 1993; 148: 1418-1426.

            2.American thoracic society board of directors. Hospital- acquired Pneumonia in Adults: Diagnosis, Assessment of Severity, Initial Antimicrobial therapy, and preventative strategies- A Consensus Statement. Am J Respir Crit Care Med. 1995; 153: 1711-1725.

            3. Camacho F, Páez J, Awad C. Enfermedades del Tórax. Colombia: Ediciones Médicas Zambon, 1992: 226.

            4. Campbell D. Overview of Community Acquired Pneumonia. Med Clin N Am. 1994; 78: 1035-1047.

            5. Carbon C. Estrategias diagnósticas y tratamiento de neumonía atípica. Iladiba 1995: 7-9.

            6. Fauci A, Braunwald E y col. Harrison's Principies of Internal Medicine. 14 ed. USA: Mc Graw- Hill Companies INC. 1998; 2: 1437-1438.

            7. Dean N. Use of prognostic scoring and outcome assessment tools in the admission decision for community-acquired pneumonia. Clin Chest Med. 1999; 20: 521-529.

            8. Heath C, Grove D, Looke D. Delay in appropriate therapy of Legionella Pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis. 1996; 15: 286-290.

            9. Pachón J, Prados D, Capote F et al. Severe Community Acquired Pneumonia, etiology, prognosis and treatment. Am Rev Respir Dis. 1990; 142: 369-373.

            10. Edwing S, Torres A. Severe Community Acquired Pneumonia. En: Clinics in Chest Medicine. 1999; 20:123-130

            11. Farr B, Sloman A, Fisch M. Predicting dead in Patients Hopitalized for Community-Acquired Pneumonia. Annals of Internal Medicine. 1991; 115: 428-436.

            12. Edelstein P. Legionaires' Disease, State-of-the-Art Clinical Article. Clinical Infectious Diseases.1993;16: 741-749.

            13. Carratala J, Gudiol F, Pallares R, Dorca J et al. Risk factors for Nosocomial Legionella Pneumophila Pneumonia. Am J Respir Crit Care Med.1994; 149: 625-629.

            14. Cunha B. Severe Community-Acquired Pneumonia Critical Care Clinics. 1998;14: 105-117.

            15. Lieberman D, Porath A, Schalaeffler F et al. Legionella species Community-Acquired Pneumonia. Chest. 1996; 109 p. 1243-1249.

            16. Feldman C. Pneumonia in the elderly. Clin Chest Med. 1999; 20: 563-573.

            17. Fiore A, Nourti P, Levine O et al. Epidemic Legionnaires' Disease: Two Decades Later: Old sources, new diagnostic methods. Clin Infect Dis. 1998; 26: 426-433

            18. Feldman C, Ross S, Goolam MA et al. The aetiology of severe community acquired pneumonia and its impact on initial, empiric, antimicrobial treatment. Resp Med.1995; 89: 187.

            19. Kohler R. Neumonía Severa: Cuando y por qué hospitalizar. Postgraduate Medicine. 1999; 6-7: 33-45.

            20. Fein A, Niederman M. Guidelines for the initial management of Community-Acquired Pneumonia: Savory Recipe or Cookboock for disaster?. Am J Resp Crit Care Med. 1995; 152: 1149-1153.

            21.Vélez H, Borrero J, Restrepo J, Rojas W. William. Neumología. 3era ed. Colombia: Corporación para Investigaciones Biológicas. 1986; 3: 583-585.

            22. OXOID Manual, 1995, publicado por Unipath, España S.A. páginas 149-151.

            23. OXOID Diagnostic Reagents. Unipath limited, Basingstoke, Hampshire, England. 1995

            24. Hirani N, Macfarlane J. Impact of management guidelines on the outcome of sever community-acquired pneumonia. Thorax. 1997; 52: 17-21.

            25. Mandel L. Antibiotic therapy for Community-Acquired Pneumonia. Clin Chest Med. 1999; 20: 589-598. Lieberman D, Porath A, sChlaeffer F et al. Legionella species Community-Acquired Pneumonia. Chest. 1996 p. 1243-1249.

            Sistema OJS 3.4.0.5 - Metabiblioteca |